Insider holders · CIK 0001658551
Amylyx Pharmaceuticals, Inc. · AMLX
Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity
| Insider | Direct shares | Indirect shares | Total reported | Last report (ET) | From |
|---|---|---|---|---|---|
| Joshua B CohenCo-Chief Executive Officer | 3,613,123 | — | 3,613,123 | Sep 14, 2026 · 4:00 pm EDT | Form 4 |
| Justin B. KleeCo-Chief Executive Officer | 3,613,056 | — | 3,613,056 | Sep 14, 2026 · 4:00 pm EDT | Form 4 |
| Camille L BedrosianChief Medical Officer | 278,064 | — | 278,064 | Sep 14, 2026 · 4:00 pm EDT | Form 4 |
| James M FratesChief Financial Officer | 233,625 | 40,000 | 273,625 | Sep 14, 2026 · 4:00 pm EDT | Form 4 |
| Gina MazzarielloChief Legal Officer | 190,838 | — | 190,838 | Sep 14, 2026 · 4:00 pm EDT | Form 4 |
| Karen FirestoneDirector | 116,900 | — | 116,900 | Sep 2, 2026 · 4:00 pm EDT | Form 4 |
Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.